Prue C Weideman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4154305/publications.pdf

Version: 2024-02-01

687363 677142 21 717 13 22 citations h-index g-index papers 23 23 23 1391 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Tamoxifen and Risk of Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Journal of Clinical Oncology, 2013, 31, 3091-3099.	1.6	148
2	10-year performance of four models of breast cancer risk: a validation study. Lancet Oncology, The, 2019, 20, 504-517.	10.7	116
3	Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). Breast Cancer Research, 2018, 20, 132.	5.0	51
4	Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. Familial Cancer, 2005, 4, 105-113.	1.9	47
5	Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast Cancer Research, 2019, 21, 52.	5.0	44
6	Do <i>BRCA1</i> and <ibrca2< i=""> Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer. Journal of Clinical Oncology, 2013, 31, 3920-3925.</ibrca2<>	1.6	42
7	Preventing breast and ovarian cancers in highâ€risk BRCA1 and BRCA2 mutation carriers. Medical Journal of Australia, 2013, 199, 680-683.	1.7	39
8	Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. Cancer Research, 2020, 80, 116-125.	0.9	37
9	iPrevent $\hat{A}^{@}$: a tailored, web-based, decision support tool for breast cancer risk assessment and management. Breast Cancer Research and Treatment, 2016, 156, 171-182.	2.5	33
10	Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk. Journal of the National Cancer Institute, 2019, 111, 331-334.	6.3	31
11	Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Breast Cancer Research and Treatment, 2010, 120, 715-723.	2.5	29
12	Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). Breast Cancer Research, 2019, 21, 128.	5.0	27
13	Cancer Risk Management Practices of Noncarriers Within <i>BRCA1/2 </i> Mutation–Positive Families in the Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer. Journal of Clinical Oncology, 2008, 26, 225-232.	1.6	19
14	Does stress increase risk of breast cancer? A 15â€year prospective study. Psycho-Oncology, 2018, 27, 1908-1914.	2.3	12
15	The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing. JMIR Formative Research, 2018, 2, e24.	1.4	10
16	Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. International Journal of Cancer, 2019, 145, 370-379.	5.1	9
17	Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. JNCI Cancer Spectrum, 2019, 3, pkz066.	2.9	8
18	Testing for Gene-Environment Interactions Using a Prospective Family Cohort Design: Body Mass Index in Early and Later Adulthood and Risk of Breast Cancer. American Journal of Epidemiology, 2017, 185, 487-500.	3.4	5

#	Article	IF	CITATIONS
19	Prostate screening uptake in Australian BRCA1 and BRCA2 carriers. Hereditary Cancer in Clinical Practice, 2007, 5, 161.	1.5	3
20	Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results. Journal of the National Cancer Institute, 2020, 112, 418-422.	6.3	1
21	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. JNCI Cancer Spectrum, 2021, 5, pkab090.	2.9	1